Dolutegravir Reduces HTLV-1 Proviral Load and Improves Neurological Outcomes in a Phase II Controlled Trial

Journal:
Clinical Infectious Diseases
Published:
DOI:
10.1093/cid/ciag163
Affiliations:
3
Authors:
9
Go to article
Institutions Authors Share
Fundação Bahiana de Infectologia (FBaI), Brazil
5.000000
 0.56
Federal University of Bahia (UFBA), Brazil
4.000000
 0.44
Interested in Clinical Sciences?